Thank you, GPha, for your kind reply. The nomenclature explanation was particularly helpful. So I am assuming that the cancer treatment with "Dostarlimab" refers to an agent targeting the immune system. On first reading of the article I posted I was concerned that we had a true competitor for NWBO, but upon further inquiry I realized that they were working with only a sample of 18 patients who had been specifically chosen. Thank you again for your thoughtful reply and welcome explanation.